Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare, and Tudou.

Venrock

Gilead Sciences

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. The company's proprietary LYNX drug delivery platform enables the creation of medicines that can last for a week or longer in an oral dosage form. This platform represents a significant advance in oral drug delivery, aiming to dramatically reduce dosing frequency compared to traditional daily pills. Lyndra's lead product candidate is oral weekly risperidone (LYN-005), which is being developed for the treatment of schizophrenia and bipolar I disorder. In January 2024, Lyndra reported positive results from the Phase III STARLYNG-1 clinical trial of LYN-005, meeting its primary endpoint. The company is also developing other long-acting oral therapies, including oral weekly dapagliflozin (LYN-045) for diabetes and oral weekly aripiprazole (LYN-006) for mental health conditions. Additionally, Lyndra is working on oral biweekly ivermectin (LYN-163) as a potential tool in the fight against malaria. The LYNX platform originated from technology invented at the Massachusetts Institute of Technology (MIT) and has progressed rapidly since 2015 through preclinical and human studies. Lyndra has a state-of-the-art GMP manufacturing facility in Lexington, Massachusetts.
Key customers and partnerships
Lyndra Therapeutics has established partnerships with several notable organizations to advance its long-acting oral therapies. The company has received product funding from the Bill & Melinda Gates Foundation, particularly for the development of oral biweekly ivermectin. In December 2023, as part of a USD 101 million Series E financing round, Lyndra entered into an agreement with Sun Pharmaceutical Industries Limited. This partnership grants Sun Pharma an exclusive license to manufacture and market Lyndra's oral weekly risperidone, dapagliflozin, and aripiprazole in six countries, including India and Brazil, pending further clinical development. Lyndra has previously received funding from AbbVie and Gilead Sciences, Inc., indicating potential interest from major pharmaceutical companies in its technology platform. The company's focus on developing therapies for conditions like schizophrenia, bipolar disorder, and opioid use disorder suggests potential future partnerships or customers in the mental health and addiction treatment sectors.

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Gritstone Bio (formerly known as Gritstone Oncology) is a biotechnology company engaged in developing tumor-specific immunotherapies for various types of cancer and infectious diseases. Its proprietary AI platform, Edge, is designed to predict tumor-specific neoantigens from a routine tumor biopsy. Based on this, the company develops immunotherapies that can drive the patient&rsquo;s immune system to attack and destroy tumors. The company claims its platform has shown a nine-fold improvement in accuracy for predicting tumors in comparison to publicly available approaches.&nbsp;
 
 
 As of March 2024, the company&rsquo;s pipeline included six drug candidates, including its lead product candidate, GRANITE, an individualized immunotherapy in Phase II/III clinical trials for microsatellite stable colorectal cancers, and SLATE, an off-the-shelf immunotherapy candidate, is in Phase II clinical trials for metastatic solid tumors.&nbsp;
 
 
 Key customers and partnerships
 
 
 Gritstone Bio has key customers that develop candidates using its technology. These include partnerships with 1) National Cancer Institute to evaluate a neoantigen cell therapy-vaccine combination using Gritstone&rsquo;s AI platform (
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-and-national-cancer-institute-nci-establish">
 February 2023
 </a>
 ), 2) Gilead Sciences to research and develop a vaccine-based immunotherapy using Gritstone&rsquo;s technology (
 <a href="https://www.gilead.com/news-and-press/press-room/press-releases/2021/2/gilead-sciences-and-gritstone-announce-collaboration-utilizing-gritstones-vaccine-platform-technology-for-hiv-cure">
 February 2021
 </a>
 ), and 3) Bluebird Bio to develop novel cancer cell therapies using Gritstone&rsquo;s AI platform (
 <a href="https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-and-gritstone-oncology-announce-strategic">
 August 2018
 </a>
 ).
 
 
 In addition, it partnered with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines using Genevant&rsquo;s lipid nanoparticle technology (
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-and-genevant-sciences-announce-option-and-license">
 August 2023
 </a>
 ) and with Friends of Cancer Research to join the ctDNA to Monitor Treatment Response (ctMoniTR) Project (
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-partners-friends-cancer-research-friends-ctdna">
 August 2023
 </a>
 ).
 
 
 Funding and financials
 
 
 The company filed for an IPO in September 2018, raising USD 100 million. In 
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-announces-private-placement-450-million">
 October 2022
 </a>
 , the company raised USD 45 million via a private placement in public equity financing. The funds were expected to be used for clinical development of oncology and infectious disease programs and for general corporate purposes.
 
 
 In 
 <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/gritstone-bio-wins-433-million-us-award-covid-vaccine-study-2023-09-27/">
 September 2023
 </a>
 , the company secured a USD 433 million contract from the US government to conduct a mid-stage study of its self-amplifying mRNA Covid-19 vaccine candidate.
 
 
 For 
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-reports-fourth-quarter-and-full-year-2023">
 FY2023
 </a>
 , it reported USD 16.3 million in revenue from collaborations, an 18% decrease YoY. Further, the company reported net losses of USD 138.5 million, increasing 16% YoY.
 
</div>

Reinventing gene therapies with next-generation technologies

Human Gene Editing

<div>
 
 Precision Biosciences specializes in gene editing to develop novel therapeutics for oncology and genetic diseases. It uses its wholly-owned genome editing platform &ldquo;ARCUS&rdquo; based on natural homing endonucleases&mdash;naturally-occurring DNA-cutting enzymes&mdash;that enable highly precise editing.
 
 
 The company develops in vivo (gene editing done inside the body) therapeutics for genetic diseases (potentially one-time treatments) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics for allogeneic Chimeric Antigen Receptors T (CAR-T) immunotherapies. As of March 2024, Precision has seven drug programs under its in vivo gene editing pipeline, with two of those (also the company&rsquo;s wholly-owned programs) in the investigational new drug (IND)-enabling stage. Precision&rsquo;s other candidates are in research stages, while its candidate being developed in partnership with iECURE, was approved for clinical testing.
 
 
 Precision operates MCAT, an in-house current good manufacturing practices (GMP)-graded manufacturing facility that enables scalable manufacturing of its products. It also operates a fully-owned subsidiary in the UK named Precision BioSciences UK Ltd.
 
 
 Key customers and partnerships
 
 
 The company has three programs in collaboration with big pharma company Eli Lilly &amp; Company. These leverage the ARCUS platform to identify drug targets for Eli Lilly. The latter was responsible for the clinical development and commercialization of the candidates afterward. The agreement was closed in January 2021, but Precision was eligible for up to USD 420 million in milestone payments. Precision also signed a similar development and licensing partnership with iECURE to develop therapies for four genetic diseases using Precision&rsquo;s PCSK9-directed ARCUS nuclease. 
 
 
 In August 2023, Precision BioSciences also secured a strategic transaction with 
 <a href="https://sp-edge.com/companies/766527">
 Imugene Limited
 </a>
 for global rights to Azercabtagene Zapreleucel (azer-cel), Precision&rsquo;s lead allogeneic cancer-related CAR T candidate. Included in the agreement is the option to develop up to three other cancer research programs in the future. As a part of the agreement, Precision will receive upfront cash and equity valued at USD 21 million. Additionally, Precision was eligible for an USD 8 million near-term payment in cash and equity upon successful completion of the phase 1b dosing in the CAR T, along with USD 198 million in additional milestone payments and double-digit royalties on net sales. For each additional research program selected by Imugene, Precision was eligible for up to USD 145 million in milestone payments and tiered royalties on net sales. 
 
 
 
 
 The company&rsquo;s other partnerships include a program purchase agreement with 
 <a href="https://contracts.justia.com/companies/precision-biosciences-inc-2978/contract/178368/">
 Servier
 </a>
 (April 2021) and a clinical trial collaboration with 
 <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-and-springworks-therapeutics-announce">
 SpringWorks Therapeutics
 </a>
 (September 2020).
 
 
 Funding and financials
 
 
 In June 2022, the company raised USD 50 million through a common stock offering. The proceeds were raised via Precision BioSciences selling 35,971,224 of its shares at a stock price of USD 1.39 per share. The company earmarked these funds to fund ongoing and planned research and development, and for working capital and general corporate purposes. For 2022, the company recorded revenue of USD 25.1 million earned through licensing and collaborations. 
 
</div>

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

Headquartered in San Francisco, Curebase primarily offers a digital e-clinical suite that supports clinical trials in conducting a range of tasks, including 1) patient-reported outcomes, 2) clinical outcome assessments, 3) electronic consent, sourcing, and scheduling of patients, and 4) interactive response technology. The platform is compliant with HIPAA GDPR, 21 C.F.R Part 11, and ICH/GCP.As of May 2022, the company had over 300 in-house staff, including clinical research coordinators, to support clients. The company had done 83 studies as of June 2024 In terms of geographic reach, Curebase operates in the US, UK, Canada, and France. Key customers and partnershipsAs of June 2024, the company’s solution had collected 8.4 million points of data, facilitated the signing of 30,000 consent forms and overseen participation from 250,000 participants across 83 studies. Some of its customers were Gilead, Johnson &amp; Johnson, Persephone Biosciences, Walgreens, Mitsubishi Tanabe Pharma, and the Mayo Clinic. In terms of geographic reach, Curebase operates in the US, the UK, Canada, and France, with plans to expand into six more countries. Funding and financialsThe company raised USD 40 million in Series B funding in May 2022 led by Gilead. The proceeds were to be used to strengthen the product team, fund expansion into six new European countries, and develop the language support for these countries.

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Tentarix Biotherapeutics is a biotechnology company focused on developing multi-functional, conditional protein therapeutics using its proprietary Tentacles platform. The company's technology produces biologics designed to activate immune cells that can modulate disease pathways while potentially mitigating safety concerns associated with non-specific targeting of other immune cells. Tentarix's approach aims to address previously undruggable targets and tackle complex immune interactions driving cancers and inflammatory diseases. The company's pipeline includes programs in oncology, immunology, and autoimmune diseases, with a focus on cell-specific reprogramming and targeted delivery. Tentarix utilizes several proprietary technologies, including CellSurf for understanding complex immune interactions, HuTARG for discovering novel human antibodies, and FunctionSeq for high-throughput screening of conditional multi-specifics.
Key customers and partnerships
In February 2024, Tentarix entered into a strategic partnership with AbbVie to discover and develop conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration leverages AbbVie's expertise in these therapeutic areas alongside Tentarix's Tentacles platform. Under this agreement, Tentarix received USD 64 million in upfront option payments from AbbVie for two programs. Previously, Tentarix announced a collaboration with Gilead Sciences to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. These partnerships validate Tentarix's approach and expand its portfolio of internal and external pipeline programs.

Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.

Leap Therapeutics is a clinical-stage biopharmaceutical company and specializes in the development of targeted and immuno-oncology therapeutics. Leap Therapeutic focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.

WeCareTn is a non-profit organization build to support transwomen. It  supports Transwomen of color through education and empowerment with the goal that they have the same equity and quality of life as envisioned.

A New Way of Life Reentry Project is a non profit organization that provides housing and reentry support to formerly incarcerated women and their children. A New Way of Life operates a total of four sober living homes, serving 40-50 women and children per year, and offers a wide range of support services to help facilitate a successful transition back to community life. Since its founding in 1998, A New Way of Life has helped transform the lives of over 220 women.

Howard University is a historically significant institution founded to provide education to African-American students. It offers a range of undergraduate, graduate, and doctoral programs, including in law, medicine, and pharmaceutical studies. Located in Washington, DC, Howard is surrounded by political and cultural influences that shape the student experience. The university is known for its competitive academic environment and distinguished faculty.

Baltimore Safe Haven provides opportunities for TLGBQ people. They providing housing services and food distributing services for TLGBQ community.

The California Black Women's Health Project is the only statewide, non-profit organization that is solely committed to ​improving the health of California's 1.2 million Black women and girls through advocacy, education, outreach and policy.

PSPRCVA offers a safe haven for Virginia's People of Color - LGBTQ+ community and other marginalised people.

AIDS United is ending the U.S. HIV epidemic through grantmaking, capacity-building, technical assistance, and advocacy.

National Association of Black Social Workers is a non-profit that aims to enhance life and empower people of African ancestry.

San Francisco Community Health Center is a health organization that focuses on advancing health, wellness, and equality in the community.

Dancing Grounds is a nonprofit organization and dance studio with adult fitness and dance classes.

Ribbon is a Center of Excellence that specializes in skill-building training and technical assistance, long-term organizational development, and leadership development.

SLK is a community- based health care organization. It promotes the prevention and eradication of illnesses and infections among vulnerable communities, especially high-risk negatives and the LGBTQ community.

BWLI is a national institute at NDRI-USA Inc., a not-for-profit research and development organization which provides high-impact actionable solutions to pressing public health problems. Its mission is to improve health and wellness for Black women across the lifespan through innovative resources, programmatic support, and culturally-relevant public health education.

Transinclusive Group is a Transgender-Led TLGBQ+ tax exempt, non-profit organization. As an advocacy driven organization, its goal is to cultivate advocates to take action to influence social, political, and economic systems to bring about change for all TLGBQ+ individuals.

Triumphant 2Gether is a tax-exempt, nonprofit organization. It empowers women and girls impacted by violence through policy advocacy and social service projects.

Unspoken Treasure Society is a non-profit organization committed to meeting the needs of our TRANS community.

WACO (Where Art Can Occur) Theater Center is a cultural institution that promotes modern African Diaspora performing and visual arts.

SisterLove is on a mission to eradicate the adverse impact of HIV/AIDS and other reproductive health challenges upon women.

Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.

Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms.  Hookipa´s TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers. Hookipa has completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV) and is finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)- related head and neck cancers.

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

CDA Foundation is a non-profit organization that specializes in the study of complex and poorly-understood diseases.

Alliance of AIDS Services provides health care services. They provide resources and charitable services for AIDS patients. They improve the health of communities impacted by HIV/AIDS through compassionate and non-judgmental prevention, support services, and connection to care.

Compassionate Atlanta is a non-profit organization that offer community building, education, and town planning services in Atlanta.

PCAF provides direct care services to HIV/AIDS patients as well as extensive outreach, education, and prevention programming.

HEROES supports, educates, and uplifts our community through adult wellness, youth education, and community service.

Transgender Services Empowerment offers dependable services with the goal of empowering the underserved transgender and LGBT communities.

Central Illinois Friends provides compassionate and personalized care to people living with HIV and vulnerable community members who require comprehensive clinical and supportive services.

MBK's objective is to improve the health and well-being of minority and marginalized people across the United States by providing leadership and engagement with the public and community healthcare providers. The HIV prevention services provided by MBK centered on developing and delivering a diverse set of educational and training programs in public health, social policy, action research, information technology, advocacy, coalition development, and capacity building. MBK built its dedication to HIV prevention among racial and ethnic minority communities through its significant expertise, as seen by its service to over 15,000 clients nationwide.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Young Survival Coalition is engaged in the critical issues unique to young women and breast cancer. They work with survivors, caregivers, medical, research, advocacy, and legislative communities to increase the life expectancy for women diagnosed with breast cancer. They also produce free educational resources, such as the breast cancer navigator series, which are comprehensive guidebooks that address every phase of treatment and survivorship.

Nueva vida goal is to educate, encourage, and empower Latinas whose lives are impacted by cancer. Nueva vida also works to promote timely access to cutting-edge cancer treatment.

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics.

Curebase builds a digital clinical trial assistant that would alter how medical providers discover, activate, and administer clinical trials for their patients. It aims to run clinical trials faster and cheaper than anyone else via software that reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics.  The company was established in 2017 and is based in San Francisco, California.

Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

Destination Tomorrow is the Black-led Transgender & Gender Non-Conforming (TGNC) grant-making agency. The Destination Tomorrow offers services that take LGBTQ/TGNC individuals off the path of requiring emergency care with a focus on economic, social and mental empowerment on a holistic level.

Gritstone bio develops immunotherapies for cancer and infectious diseases. They started with tumor-specific neoantigens and their programs to include viral antigens displayed on the surface of the virally infected cells. Their biological immune system recognition of targets on the surface of abnormal cells is common to anti-tumor and anti-viral immunity. With the development and commercialization of immunotherapy drugs including checkpoint inhibitors, the field of immuno-oncology is transforming the treatment of patients with cancer.

Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused on three core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy.

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.

Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis.  Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.

Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its  Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease.  The company was founded in 2016 and is based in Cambridge, Massachusetts.

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

The National AIDS Memorial relies solely on funding from longtime personal donors and corporate partners to support its mission as a dedicated space in the national landscape where millions of Americans touched directly or indirectly by AIDS can gather to heal, hope, and remember. The National AIDS Memorial, known as “the Grove”, was created more than twenty-eight years ago in San Francisco’s Golden Gate Park at the height of the HIV/AIDS epidemic as a place where those impacted by AIDS could both grieve and begin the process of healing. In 1996, legislation sponsored by U.S. Representative Nancy Pelosi was signed into law by President Clinton that elevated “the Grove” as this nation's sole federally-designated National AIDS Memorial. More than 50,000 individuals from around the world have contributed 225,000 volunteer hours to support the National AIDS Memorial and its mission.

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases. Gilead's primary areas of focus include HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions.

<div> Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need in the US, Europe, and internationally. Founded in 1987 and headquartered in Foster City, California, Gilead operates in over 35 countries worldwide. Gilead's product portfolio includes treatments for HIV/AIDS, liver diseases, hematology, oncology, and inflammation. The company's key products include Biktarvy, Genvoya, Descovy, and Truvada for HIV/AIDS; Epclusa, Harvoni, and Vemlidy for viral hepatitis; Veklury for Covid-19; and oncology drugs like Trodelvy. Gilead's HIV franchise, particularly Biktarvy, continues to be a major revenue driver, accounting for about 46% of product sales as of Q2 2024. The company is also expanding its presence in oncology, with sales in this segment growing 15% year-over-year in Q2 2024. <ul> <li> Biktarvy: Leading HIV treatment with 8% sales growth in Q2 2024 </li> <li> Epclusa, Harvoni, Vemlidy: Treatments for viral hepatitis </li> <li> Veklury: Injection for intravenous use to treat Covid-19 </li> <li> Trodelvy: Oncology drug with 23% sales growth in Q2 2024 </li> </ul> Gilead reported total product sales of USD 6.7 billion in Q2 2024, a 6% increase year-over-year. The company is focused on advancing its pipeline, particularly in HIV prevention and liver diseases. In February 2024, Gilead acquired CymaBay Therapeutics to expand its liver disease portfolio. The company's HIV prevention drug lenacapavir showed 100% efficacy in Phase 3 trials, potentially replacing daily pills with two shots per year. Gilead also received FDA approval for Livdelzi to treat primary biliary cholangitis in 2024. The company aims to file for approval of lenacapavir as an HIV prevention option by the end of 2024, with potential market launch in 2025. </div>

Gilead Sciences to Present at Upcoming Investor Engagements

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 
 Genesis Therapeutics, an AI-focused biotechnology company, has partnered with Gilead Sciences, a biopharmaceutical company, to develop new small-molecule therapies for multiple targets. Genesis will receive a $35 million upfront payment for three targets, and there are prospects for additional payments and royalties upon product commercialization.
 The partnership will use Genesis' AI platform, Genesis Exploration of Molecular Spaces (GEMS), to produce and improve molecules for targets selected by Gilead. Both companies will participate in preclinical research together, with Gilead retaining exclusive rights for any potential clinical development and commercialization.
 
</div> Analyst QuickTake: 
 The company’s GEMS platform has been deployed in several Big Pharma drug development partnerships, including with <a href="https: 
//sp-edge.com/updates/1029"> Genentech </a> , a subsidiary of Roche (October 2020), and <a href="https: 
//www.businesswire.com/news/home/20220503005444/en/Genesis-Therapeutics-Announces-Strategic-Collaboration-with-Lilly-to-Discover-Novel-Therapies-Using-the-Genesis-Molecular-AI-Platform"> Eli Lilly </a> (May 2022). The platform, which combines 3D structure-aware deep neural networks with molecular simulation technology, was used for lead optimization and target identification by the companies.

Gilead Sciences

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless